知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

53 records (took 0.021 seconds)

    SELECTION OF IMMUNE CELLS USING PEPTIDE MHC COMPLEXES GENERATED BY CONDITIONAL LIGAND EXCHANGE
    1.
    发明公开
    SELECTION OF IMMUNE CELLS USING PEPTIDE MHC COMPLEXES GENERATED BY CONDITIONAL LIGAND EXCHANGE 审中-公开

    公开(公告)号：US20240358831A1

    公开(公告)日：2024-10-31

    申请号：US18685736

    申请日：2022-08-24

    Applicant: IMMATICS US, INC. ,  Immatics Biotechnologies GmbH

    Inventor： Stefanie SPALT ,  Claudia WAGNER ,  Dominik MAURER ,  Heiko SCHUSTER ,  Steffen WALTER

    IPC: A61K39/00 ,  C07K14/74 ,  C12N5/0783

    CPC classification number: A61K39/4632 ,  A61K39/4611 ,  C07K14/70539 ,  C12N5/0636 ,  C12N2502/11

    Abstract: The present invention relates to a method for selecting an immune cell expressing on its surface an antigen-binding protein specifically binding to a complex of a peptide A (PA) and a Major Histocompatibility Complex (MHC) molecule, comprising the steps of (i) providing a plurality of immune cells expressing different antigen-binding proteins; (ii) contacting the plurality of immune cells with a first composition comprising a complex 1A, comprising a MHC molecule 1 (M1) and a peptide A (PA), and a complex 1X, comprising M1 and a peptide B (PB); (iii) contacting the plurality of immune cells with a second composition comprising a complex 2A, comprising a MHC molecule 2 (M2) and PA, and a complex 2X, comprising M2 and a peptide C (PC); (iv) selecting from the plurality of immune cells a cell expressing an antigen binding protein that specifically binds to complex 1A, wherein complexes 1X and 2X, but not 1A and 2A, dissociate upon stimulation with a defined chemical or physical stimulus; and wherein the amino acid sequences of PB and PC differ in at least one amino acid. The invention further relates to an immune cell selected by the method according to the invention, a method of treatment using said immune cell, a kit for selecting a cell expressing on its surface an antigen-binding protein, and a peptide suitable for use in the method according to the invention.

    DUAL SPECIFICITY POLYPEPTIDE MOLECULE
    6.
    发明申请
    DUAL SPECIFICITY POLYPEPTIDE MOLECULE 审中-公开

    公开(公告)号：US20190016801A1

    公开(公告)日：2019-01-17

    申请号：US16035403

    申请日：2018-07-13

    Applicant: Immatics Biotechnologies GmbH

    Inventor： Martin HOFMANN ,  Felix UNVERDORBEN ,  Sebastian BUNK ,  Dominik MAURER

    IPC: C07K16/28 ,  C07K16/10 ,  C07K16/30

    Abstract: The present invention relates to a bispecific polypeptide molecule comprising a first polypeptide chain and a second polypeptide chain providing a binding region derived from a T cell receptor (TCR) being specific for a major histocompatibility complex (MHC)-associated peptide epitope, and a binding region derived from an antibody capable of recruiting human immune effector cells by specifically binding to a surface antigen of said cells, as well as methods of making the bispecific polypeptide molecule, and uses thereof.

    NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME
    10.
    发明申请
    NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME 有权

    公开(公告)号：US20210388079A1

    公开(公告)日：2021-12-16

    申请号：US17397656

    申请日：2021-08-09

    Applicant: Immatics Biotechnologies GmbH

    Inventor： Claudia WAGNER ,  Leonie ALTEN ,  Sebastian BUNK ,  Dominik MAURER

    IPC: C07K16/26 ,  C07K14/725 ,  C07K14/81 ,  C07K16/28 ,  C07K16/38 ,  C12N15/85 ,  C12N5/0783

    Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular the TAA Serine protease inhibitor Kazal-type 2 (SPINK2). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and SPINK2 binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of SPINK2 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

Patent Agency Ranking